Daxor’s BVA-100 diagnostic featured at MedAxiom CV Transforum Fall ’24

Daxor will be exhibiting at the MedAxiom Cardiovascular Transforum Fall’24 Conference being held at the Gaylord Rockies Resort & Convention Center in Aurora, CO, October 17-19, 2024. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting cardiovascular thought-leaders from across the country to transform cardiovascular care together with leading industry innovators. “We look forward to engaging with industry leaders at this pivotal gathering, connecting with top cardiovascular innovators to demonstrate how our blood volume analysis technology directly tackles key challenges: hospital readmissions, mortality rates, and resource optimization. MedAxiom’s reputation for introducing outcome-improving, cost-reducing solutions makes this the ideal platform to highlight our technology,” said Michael Feldschuh, Daxor’s CEO. BVA guided care has been shown in peer-reviewed studies to significantly improve multiple measures of patient outcomes, including reduction in 30-day mortality by 82%, 1-year mortality by 86%, 30-day readmissions by 56%, and also results in a 57% reduction in length of stay when performed upon admission. BVA technology provides clinicians with 98% accurate, actionable data to optimize treatment plans and individualize care, improving outcomes while reducing duration and cost.